Zimmer Biomet Holdings, Inc. ZBH
91.04
1.35
1.51%
as of 25 Sep
- Market cap
- $17.1B
- P/E
- 22.0×
Follow ZBH
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Zimmer Biomet Holdings, Inc. (ZBH) Return on equity
Zimmer Biomet Holdings, Inc.'s return on equity over the twelve months to 30 June 2026 was 6.41%, up 0.8 percentage points from fiscal 2025 (5.60%). Over the past ten years it has ranged from −3.30% (fiscal 2018) to 17.0% (fiscal 2017); the current reading is higher than 64% of that period. That is above the Medical Devices industry median of −15.3% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | 5.60% | (1.64) |
| FY2024 | 7.24% | (1.11) |
| FY2023 | 8.35% | 6.48 |
| FY2022 | 1.87% | (1.36) |
| FY2021 | 3.23% | 4.36 |
| FY2020 | −1.13% | (10.69) |
| FY2019 | 9.56% | 12.86 |
| FY2018 | −3.30% | (20.25) |
| FY2017 | 17.0% | 13.82 |
| FY2016 | 3.13% | 1.34 |
Against its own ten years
Low −3.30%
High 17.0%
Ten-year median
3.23%
Current reading's percentile
64
Return on equity against peers
| Company | Return on equity |
|---|---|
| GEHC GE HealthCare Technologies Inc. compare | 19.2% |
| GMED Globus Medical, Inc. compare | 11.8% |
| PEN Penumbra, Inc. compare | 11.4% |
| STE STERIS plc compare | 11.4% |
| PHG Koninklijke Philips N.V. compare | 10.2% |
| ZBH Zimmer Biomet Holdings, Inc. | 6.41% |
| BIO Bio-Rad Laboratories, Inc. compare | 3.11% |
| BIO.B Bio-Rad Laboratories, Inc. compare | 3.11% |
| SNN Smith & Nephew SNATS, Inc. compare | 0.00% |
| Medical Devices industry median | −15.3% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on ZBH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement